Nature Communications (Nov 2019)

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

  • Jacqueline H. L. Fok,
  • Antonio Ramos-Montoya,
  • Mercedes Vazquez-Chantada,
  • Paul W. G. Wijnhoven,
  • Valeria Follia,
  • Neil James,
  • Paul M. Farrington,
  • Ankur Karmokar,
  • Sophie E. Willis,
  • Jonathan Cairns,
  • Jenni Nikkilä,
  • David Beattie,
  • Gillian M. Lamont,
  • M. Raymond V. Finlay,
  • Joanne Wilson,
  • Aaron Smith,
  • Lenka Oplustil O’Connor,
  • Stephanie Ling,
  • Stephen E. Fawell,
  • Mark J. O’Connor,
  • Simon J. Hollingsworth,
  • Emma Dean,
  • Frederick W. Goldberg,
  • Barry R. Davies,
  • Elaine B. Cadogan

DOI
https://doi.org/10.1038/s41467-019-12836-9
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 15

Abstract

Read online

DNA-dependent protein kinase (DNA-PK) plays a major role in the DNA damage response upon double-strand break formation. Here, the authors show that the DNA-PK inhibitor AZD7648, enhances the activity of radiotherapy, chemotherapy and the PARP inhibitor olaparib in multiple mouse tumour models.